Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy

Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz
January 2009
Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66
Academic Journal
Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the last few years, thorough analysis of the mechanism underlying tyrosine kinase's activity led to novel cancer therapy using TKs blockers. These drugs are remarkably effective in the treatment of various human tumors including head and neck, gastric, prostate and breast cancer and leukemias. The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia. The introduction of STI571 for the treatment of leukemia in clinical oncology has had a dramatic impact on how this disease is currently managed. Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase. The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava). Herein, we discuss the chemistry, biological activity and clinical potential of new drugs with tyrosine kinase blockers for cancer treatment.


Related Articles

  • Targeted therapies for CML: practical considerations and comparisons. Blamble, Debbie; Michaud, Laura Boenhnke // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14 

    The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib...

  • A Critical History of Chromic Myeloid Leukemia. Baccarani, Michele; Pane, Fabrizio // Mediterranean Journal of Hematology & Infectious Diseases;2014, Vol. 6 Issue 1, p1 

    The author reflects on various developments in treatment of chronic myeloid leukemia (CML), a cancer of white blood cells (WBCs). Topics discussed include development of targeted treatments for CML such as by targeting the tyrosine kinase inhibitors (TKIs), history of treatment of CML such as by...

  • Imatinib en première ligne dans la LMC en 2012: un traitement « dépassé » ? Giraudier, S. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p579 

    The initial management of chronic myeloid leukemia (CML) in chronic phase is now based solely on treatment with tyrosine-kinase inhibitor (TKI). The development of second generation inhibitors and their use in first-line treatment raises the issue of choice of TKI in the first prescription....

  • Faktori koji utiču na postizanje i postojanost citogenetskog odgovora kod bolesnika sa hroničnom mijeloidnom leukemijom na terapiji imatinibom. Ćojbašić, Irena; Mačukanović-Golubović, Lana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Nov2011, Vol. 68 Issue 11, p911 

    Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease. The aim of this study was evaluation and analysis of cytogenetic response in different...

  • Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Shah, Neil P. // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p49 

    The small molecule BCR-ABL-selective kinase inhibitor imatinib is the single most effective medical therapy for the treatment of chronic myeloid leukemia (CML). Although imatinib is highly effective initially and generally well tolerated, for patients who undergo relapse or disease progression...

  • Imatinib.  // Reactions Weekly;1/20/2007, Issue 1135, p18 

    The article discusses a case report on the side effects of imatinib. It references a study by J. C. Pascual et al, published in the December 2006 issue of the "International Journal of Dermatology." It presents two cases of old women who developed lichenoid eruptions during treatment with...

  • Inhibiteurs de tyrosine-kinase de 2 génération et associations: perspectives. Coiteux, V. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p601 

    Second-generation tyrosine-kinase inhibitors enable an earlier and higher quality molecular response to be achieved than with imatinib in patients suffering from CML in chronic phase at diagnosis. This implies that in the future a larger number of patients will be candidates for the...

  • Omacetaxine as an Anticancer Therapeutic: What is Old is New Again. Wetzler, Meir; Segal, David // Current Pharmaceutical Design;1/1/2011, Vol. 17 Issue 1, p59 

    No abstract available.

  • Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? RUMJANEK, Vivian M.; VIDAL, Raphael S.; MAIA, Raquel C. // Bioscience Reports;2013, Vol. 33 Issue 6, p875 

    The hallmark of CML (chronic myeloid leukaemia) is the BCR (breakpoint cluster region)-ABL fusion gene. CML evolves through three phases, based on both clinical and pathological features: a chronic phase, an accelerated phase and blast crisis. TKI (tyrosine kinase inhibitors) are the treatment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics